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We monitored the SARS-CoV-2 antibody response in 7 dogs and 2 cats by using two 
multispecies ELISA tests, plaque reduction neutralisation test and virus neutralization. 
SARS-CoV-2 neutralizing antibodies in pets persisted up to 10 months since the first positive 
testing, thus replicating observations in COVID-19 human patients. 
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Text  
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been found to infect a 
plethora of mammals, including dogs and cats (Decaro et al., 2021a). There are some 
reports of SARS-CoV-2 active infection and/or detection of specific antibodies in domestic 
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2021). While several studies have found that SARS-CoV-2 neutralizing antibodies can 
persist from 6-8 months to more than 12 months in humans (Chia et al., 2021; Dispinseri et 
al., 2021; Knies et al., 2021; Sonnleitner et al., 2021), no data are available about the 
persistence of the antibody response in dogs and cats. Here, we report the results of a 
longitudinal study in SARS-CoV-2 seropositive pets demonstrating the persistence of 
neutralizing antibodies for up to 10 months in some animals. 
The pets included 7 dogs and 2 cats, which had SARS-CoV-2 neutralizing antibodies 
according to previous studies (Patterson et al., 2020; Decaro et al., 2021b) or at a first 
screening (Table 1). The age of the tested animals ranged from 1.5 to 11 years and from 7 
to 17 years for dogs and cats, respectively. All 7 dogs and 1 of 2 cats were from COVID-19 
positive households, but none of the sampled animals had developed COVID-19 clinical 
signs. Only one dog (Dog 7) had been found to shed SARS-CoV-2 RNA by real-time PCR 
(Decaro et al., 2021b). For pets living in COVID-19 households, sera collection was initially 
carried out between 7 and 60 days after SARS-CoV-2 molecular detection in their owners. 
Sera were collected at different time points, according to the owners’ convenience and were 
tested with two commercial multispecies ELISA kits, ID Screen® SARS-CoV-2 Double 
Antigen Multi-species ELISA (ID.vet, Grabels, France) and EradikitTM COVID19 Multispecies 
(In3Diagnostic, Turin, Italy), with a plaque reduction neutralization test (PRNT) (Patterson et 
al., 2020) and with virus neutralization (VN) (Zhang et al., 2020). The results showed that 4 
of 7 dogs and 2 of 2 cats had SARS-CoV-2 neutralizing antibodies at 8 months or more after 
the first positive testing (Table 1). For one dog that had tested positive for SARS-CoV-2 by 
real-time RT-PCR (Decaro et al., 2021b), sera were available only for the first three months 
after infection and displayed antibodies through PRNT and VN at all time points. The 
remaining two dogs tested positive by PRNT and VN only at the first sampling, which may 




This article is protected by copyright. All rights reserved. 
 
4 
since these animals were infected during the first wave of the COVID-19 pandemic 
(Patterson et al., 2020). A great discrepancy was observed between serological tests based 
on ELISA and neutralization tests. Five dogs that were seropositive by PRNT and/or VN at at 
least one time point were completely negative by both commercial ELISA tests. The dog 
(Dog 7) that had been found positive for SARS-CoV-2 RNA (Decaro et al., 2021b) was 
constantly seropositive by both PRNT and VN, but invariably negative by the ID.vet ELISA 
and positive at 2 out of 3 time points by the In3Diagnostic ELISA. In contrast, the 
discrepancy between PRNT and VN was less evident, being generally restricted to few sera 
with low neutralizing antibody titers. The discrepancy between ELISA and neutralization 
tests may be related to a lower sensitivity of ELISA or, alternatively, to a lack of specificity of 
neutralization assays. However, the latter hypothesis could be ruled out since our previous 
experiments have demonstrated that pre-pandemic sera that were antibody positive for 
endemic coronaviruses of dogs and cats test negative by SARS-CoV-2 neutralization assays 
(Patterson et al., 2020; Zhang et al., 2020; Decaro et al., 2021b). The lower sensitivity of 
ELISA compared to VN or PRNT may be due to a different kinetic between the antibody 
response raised against the viral nucleoprotein (the antigen used in both ELISA tests) and 
that directed against the spike protein (the main target of neutralizing antibodies). 
Interestingly, for Cat 1 there was no evidence for exposure to COVID-19 positive human 
patients. Therefore, it is likely that this cat was infected by an asymptomatic owner with 
undiagnosed SARS-CoV-2 infection or, alternatively, it acquired the virus from other infected 
people or animals.   
Despite the increasing number of reports of SARS-CoV-2 infection in dogs and cats, no 
long-term monitoring has been carried out so far to evaluate the persistence of specific 
antibodies in pets. To our knowledge, the antibody response in pets has been monitored for 




This article is protected by copyright. All rights reserved. 
 
5 
no evidence of seroreversion (Hamer et al., 2021). Zhang et al. (2020) followed two cats for 
about 4 months, finding that neutralizing antibodies peaked after 10 days from the first 
sampling and then decreased to detection limit in 110 days. Our study, which was conducted 
using 4 different serological assays, demonstrates that similar to humans, dogs and cats 
may develop a long-term neutralizing antibody response against SARS-CoV-2. At which 
extent the presence of neutralizing antibodies is able to protect these animals from SARS-
CoV-2 reinfection is currently unknown, thus requiring further studies.  
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a Values in brackets represent the ratio between the optical densities of the tested serum and 
the positive control (cut-off value = 50%). 
b Values in brackets represent the ratio between the optical densities of the tested serum and 
the positive control (cut-off value = 20%). 
c Antibody titer is expressed as the highest serum dilution with 80% reduction in plaques in 
inoculated VERO-E6 cells 
compared to the control, with 1:20 being the lowest serum dilution tested. 
d Antibody titer is expressed as the highest serum dilution giving 100% reduction of 
cytopathic effect in inoculated VERO-E6 cells, with 1:10 being the lowest serum dilution 
tested. 
ELISA, enzyme-linked immunosorbent assay; PRNT80, plaque reduction neutralization test; 
VN, virus neutralization; 
ND, not done; Neg, negative; Pos, positive; >QR, above the quantification range. 
 
